Invest-in-America
3 주 전
OCEA: You have totally MIS-interpreted my post there, Bro. "Malaria" is simple NOT a 'trending' disease of ANY import whatsoever to DEVELOPED NATIONS. THAT's why this didn't sustain a LONG soaring period. In the identical vane that King Trump & his mindless RE-TRUMPLICAN PARTY minions could care less about the 100,000+ innocent Arabic kids, women, & men that the reprobate nation of Israel has slaughtered in the past nearly 2-years now. (But nonetheless, this OCEA STOCK indeed did move-up nicely, right?? MAKE THAT MONEY, Dude, which you surely did.)
tw0122
3 주 전
...These findings, led by Ocean Biomedical’s Scientific Co-founder Dr. Jack A. Elias in collaboration with researchers at Yale University and Brown University, were published in Translational Oncology and mark the first description of the role of chitinase 3-like-1 (CHi3L1) in EGFR-mutant cancers. The research underscores the ability of Ocean Biomedical’s novel antibody to suppress CHi3L1 activity, leading to significant tumor reduction and, crucially, the reversal of drug resistance in preclinical models.As part of its continued commitment to developing next-generation cancer therapeutics, Ocean Biomedical is initiating preclinical studies to advance its immunotherapy program and will engage with the FDA this year to align on a regulatory pathway for first-in-human trials.Industry Momentum: Bispecific Antibodies Leading a ‘Gold Rush’ in OncologyOcean Biomedical’s advancements come at a time when the oncology field is shifting its focus towardsbispecific antibodies, an innovative therapeutic class designed to target multiple cancer mechanisms simultaneously. Bispecific antibodies that target PD-1/PD-L1 and VEGF have shown remarkable efficacy in recent clinical studies, with leading biotech and pharmaceutical companies rapidly investing in this space.Merck’s recent $588 million acquisition of LaNova’s LM-299, a PD-1/VEGF bispecific antibody currently in early-stage clinical trials, underscores the high-value potential of this technology. Industry experts suggest that this wave of investments mirrors the early days of checkpoint inhibitors, highlighting the significant opportunity for Ocean Biomedical to position itself at the forefront of the next major oncology breakthrough.Ocean has also developed bispecific antibodies that combine its anti-CHI3L1 antibody and anti-PD-1 or anti-CTLA4. Studies with these bispecific antibodies have highlighted their impressive efficacy in suppressing tumor growth and progression in preclinical models of NSCLC, malignant melanoma and glioblastoma.Ocean’s Board Chair and Co-Founder Statement on Market Potential and Investor Opportunity“Our latest findings open an exciting new avenue in lung cancer treatment by demonstrating a potential solution to osimertinib resistance, a critical unmet need for patients worldwide,” said Dr. Chirinjeev Kathuria, Ocean’s Board Chair and Co-Founder. “With the industry shifting towards next-generation bispecific antibodies, Ocean Biomedical is strategically positioned to capitalize on this momentum in a variety of diseases including NSCLC, malignant melanoma and glioblastoma. The recent $588 million acquisition of LaNova’s LM-299 validates the enormous market potential in this space, and we believe our innovative immunotherapy platform could drive significant value for both patients and investors.”Expanding Therapeutic ApplicationsThe company’s lead oncology program is poised for multiple therapeutic applications:As a standalone therapy for EGFR-mutant NSCLC,In combination with existing TKIs to extend therapeutic response duration,As a salvage therapy to restore treatment efficacy in resistant tumors.
Next Steps: FDA Alignment and Preclinical AdvancementsWith plans to initiate preclinical studies this year, Ocean Biomedical is actively preparing for discussions with the FDA to determine the regulatory pathway for clinical development. This milestone marks a significant step toward bringing its innovative cancer therapy to patients in need.
Invest-in-America
1 월 전
OCEA: Not to beat-a-dead-horse (or MARE?), but those WOMEN's issues are really SICK elements of Global Society. When will it CHANGE for good? For starters, when Women no longer are required to take the LAST NAME of MEN when they get married!!! Yes, those recent "CONTRACTUAL MARRIAGES" are a good step in the right direction, for ALL parties thereto, but you know what it all means.
Invest-in-America
1 월 전
OCEA: And now, headed for RED INK momentarily!! (JUNK!! And again I must emphasize, Planet Earth could give a FLUCK about any 4th-World diseases, like MALARIA!! I myself should have known better!! Just like in the USA, stock news about any WOMEN'S disease, Cancer, etc., NEVER soars in price!!)
Invest-in-America
1 월 전
OCEA: Hugely disappointing right now, for sure; but give it a half hour more here, & it might show a reasonable up-tick behind such news. (But then, MALARIA is a 4th-World malady and, as such, DEVELOPED nations likely don't give-a-fluck about such DEAD folks. In the same manner that TRUMP doesn't give-a-fluck about so-called "ILLEGAL ALIENS".)